Treatment of Metastatic Breast Carcinoma Refractory to Doxorubicin with Liposomal-Annamycin
Abstract
We studied the toxicity and antitumor activity of Liposomal/Annamycin in patients with metastatic breast carcinoma. Sixteen patients have been treated. Toxicity was mild and consisted mostly of bone marrow suppression, particularly granulocytopenia. Non hermatological toxicity was less than what is usually seen with other anthracyclines. No responses have been seen. The study is continuing accruing a total of 12 additional less heavily retreated patients
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2000
- Accession Number
- ADA389581
Entities
People
- Aysegul A. Sahin
Organizations
- The University of Texas MD Anderson Cancer Center